^
Association details:
| Biomarker: | ALK G1202L |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report
Published date:
12/30/2020
Excerpt:
...we report the efficacy of lorlatinib upon the detection of a novel ALK G1202L after progression on brigatinib….Our report reveals the efficacy of lorlatinib in targeting ALK G1202L and can serve as an option for the clinical management of patients with ALK-rearranged lung adenocarcinoma after acquiring G1202L-mediated resistance from prior ALK inhibitor therapy.
DOI:
10.1080/15384047.2020.1836947
